Comparative study of drug interaction with CYP2C19 substrate by Vonoprazan and Esomeprazole in healthy adults

Comparative study of drug interaction with CYP2C19 substrate by Vonoprazan and Esomeprazole in healthy adults - Comparative study of drug interaction with CYP2C19 substrate by Vonoprazan and Esomeprazole in healthy adults

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029539

Enrollment

Registered

2017-10-13

Start date

2017-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Phase1: Baseline data is obtained by orally administering Atobacon proguanil combination tablet. Phase2: Inhibitor 1 Esomeprazole magnesium hydrate 20 mg is continuously administered orally for 5 con

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy volunteers

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Concentration of esomeprazole, Vonoprazan in plasma Plasma and urinary concentrations of atovaquone / cycloguanil	—

Secondary

Measure	Time frame
endogenous metabolites which change with administration of inhibitor are identified.	—

Countries

Japan

Contacts

Public Contactryokan funakoshi

Kameda Medical Center Pharmacy

funakoshi.ryokan@kameda.jp04-7099-1274

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026